Author

D. Engle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. F. Pinto· 1 shared A. Mielgo· 1 shared A. R. Atkins· 1 shared A. Taylor· 1 shared C. E. Antal· 1 shared C. Fraser· 1 shared C. Liddle· 1 shared C. Rainer· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. F. Pinto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression

G. Liang, T. G. Oh, N. Hah, H. Tiriac, Y. Shi, M. L. Truitt, C. E. Antal, A. R. Atkins, Y. Li, C. Fraser, S. Ng, A. F. Pinto, D. C. Nelson, S. Bashi, E. Banayo, , R. M. Evans

This study shows that inhibiting stromal Class I HDACs reduces pancreatic cancer progression by targeting desmoplastic and pro-tumorigenic programs in cancer-associated fibroblasts.

Nature Communications · Dec 6, 2023Peer-reviewedCancer Biology

Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer

V. Quaranta, C. Rainer, S. R. Nielsen, M. Raymant, M. S. Ahmed, D. Engle, A. Taylor, T. Murray, F. Campbell, D. Palmer, D. Tuveson, A. Mielgo, M. Schmid

This study shows that macrophage-derived granulin promotes resistance to immune checkpoint inhibitors in metastatic pancreatic cancer by excluding CD8+ T cells, and blocking granulin improves anti-tumor immunity.

bioRxiv · Dec 15, 2017Cancer Biology